PARP1 and hepatocellular carcinoma: Of note, BT-474 and HCC-1954 correspond to HER2-positive cancer subtype, and the efficacy of combining of metformin and olaparib would be consistent with PARP-inhibition leading to an increase of glycolysis by rising NAD+ and metformin counteracting this activity [49, 50].